Nicotinamide riboside is uniquely and orally bioavailable in mice and humans

Trammell SAJ, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, et al. | Nature Communications | 2016 | Evidence: strong

View on PubMed → | DOI | Publisher

Plain-language summary

Published 2016 in Nature Communications, this work by Trammell SAJ and collaborators tackles a specific question within compare-focused NMN/NAD+ research.

Key findings reported by the authors

Demonstrated oral NR bioavailability in humans
Frequent comparator paper for NMN bioavailability claims
Brenner's lab - opposing camp to Imai's NMN focus

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the strong end of the evidence spectrum. Strong-tier human placebo-controlled trial data carries the most weight in our editorial framework - treat findings as actionable signal, but always pair with at least one replication. Findings here are most directly relevant to compare decisions, with secondary relevance to science. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.

Where we cite this paper

← Back to research index